ePrints

Poly(ADP-ribose)polymerase (PARP) Inhibitors: From Bench to Bedside

Lookup NU author(s): Professor Ruth Plummer

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Poly(ADP-ribose) polymerase (PARP) inhibitors are a novel class of anticancer agents that target the DNA damage response pathways. The enzyme target, PARP, plays a key role in signalling DNA single-strand breaks. Clinical development to date has focused on their potential role in combination with DNA-damaging chemotherapy, where efficacy has been limited by enhanced normal tissue toxicity, and as single agents in the context of synthetic lethality. This article reviews these data in the context of future development as radio-potentiating agents. (C) 2014 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Publication metadata

Author(s): Plummer R

Publication type: Article

Publication status: Published

Journal: Clinical Oncology

Year: 2014

Volume: 26

Issue: 5

Pages: 250-256

Print publication date: 01/05/2014

Online publication date: 04/03/2014

Acceptance date: 11/02/2014

ISSN (print): 0936-6555

ISSN (electronic): 1433-2981

Publisher: W.B. Saunders Co. Ltd

URL: http://dx.doi.org/10.1016/j.clon.2014.02.007

DOI: 10.1016/j.clon.2014.02.007

Altmetrics

Share